Clinical Trial Update: BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases [Phase 2]

View source ↗

Summary

Phase 2 clinical trial (BITS-TO-HCC) in recruiting evaluating hepatic arterial infusion chemotherapy plus iparomlimab and tuvonralimab with bevacizumab and SBRT…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Hepatocellular Carcinoma, Portal Vein Tumor Thrombus | Phase 2 | Status: RECRUITING